Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle
Aug 20, 2025 20:30 HKT |  |
|
創新疫苗引擎持續驅動 康希諾開啟新增長週期
Aug 20, 2025 20:22 HKT | |
|
创新疫苗引擎持续驱动 康希诺开启新增长周期
Aug 20, 2025 20:02 HKT | |
|
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
Aug 19, 2025 15:00 HKT |  |
|
康哲药业（867.HK，8A8.SG）上半年营收净利双升 战略转型跑出增长新动能
Aug 19, 2025 11:53 HKT | |
|
康哲藥業（867.HK，8A8.SG）上半年營收淨利雙升 戰略轉型跑出增長新動能
Aug 19, 2025 11:53 HKT | |
|
中国生物制药（1177.HK）公布2025中期业绩
Aug 18, 2025 19:11 HKT |  |
|
中國生物製藥（1177.HK）公佈2025中期業績
Aug 18, 2025 19:11 HKT | |
|
Sino Biopharm (1177.HK) Announces 2025 Interim Results
Aug 18, 2025 19:11 HKT | |
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Aug 15, 2025 20:15 HKT |  |
|
艾曲莫德入選《2025 ACG臨床指南：成人潰瘍性結腸炎》，獲強烈推薦用於中重度潰瘍性結腸炎的誘導緩解及維持緩解治療
Aug 15, 2025 20:07 HKT | |
|
艾曲莫德入选《2025 ACG临床指南：成人溃疡性结肠炎》，获强烈推荐用于中重度溃疡性结肠炎的诱导缓解及维持缓解治疗
Aug 15, 2025 19:56 HKT | |
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
Aug 14, 2025 18:00 HKT | |
|
雲頂新耀維長寧（艾曲莫德）在中國台灣新藥上市申請獲受理 亞洲市場准入再迎里程碑
Aug 14, 2025 17:12 HKT | |
|
云顶新耀维长宁（艾曲莫德）在中国台湾新药上市申请获受理 亚洲市场准入再迎里程碑
Aug 14, 2025 17:12 HKT | |
|
NMPA已受理亿胜生物关于EB12-20145P（HLX04-O）用于治疗湿性年龄相关性黄斑变性的生物制品许可申请
Aug 13, 2025 21:25 HKT |  |
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Aug 13, 2025 20:24 HKT | |
|
NMPA已受理億勝生物關於EB12-20145P（HLX04-O）用於治療濕性年齡相關性黃斑變性的生物製品許可申請
Aug 13, 2025 20:24 HKT | |
|
Kangji Medical Receives Privatisation Proposal from a Consortium Led by Kangji Medical's Chairman, Zhong Ming, TPG and QIA to Advance Long-Term Strategic Vision
Aug 13, 2025 11:27 HKT |  |
|
康基医疗收到由董事长钟鸣、TPG及卡塔尔投资局(QIA)牵头财团提出的私有化要约 助力公司实现长远愿景
Aug 13, 2025 09:27 HKT | |
|